Neose receives milestone payment from Novo Nordisk

By Angela McDaniels

Seattle, Feb. 9 - Neose Technologies Inc. has received a research milestone payment from Novo Nordisk A/S under its recently expanded license agreement, according to a company news release.

Under the agreement, Novo Nordisk is using Neose's GlycoPEGylation technology to develop a new version of a therapeutic protein it currently markets.

Neose is a biopharmaceutical company based in Horsham, Pa., that uses enzymatic technologies to develop improved drugs.

Novo Nordisk is a Copenhagen, Denmark-based health care company that manufactures and markets pharmaceutical products for haemostasis management, growth hormone therapy, hormone replacement therapy and for the treatment of diabetes.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.